Trending Now: (CMMB) Makes Approx. 18% Early Move Following Breakings News

*Sponsored Krypton Street Has Chemomab Therapeutics (Nasdaq: CMMB) Locked In On Our Radar for This Morning—Thursday 3/27/2025. And Here’s What We Can Tell You—Right Now… With Fewer Than 17M Shares Listed, Chemomab Therapeutics (Nasdaq: CMMB) Has The Kind Of Potential That Could Amplify Moves  If Attention Builds. Maxim Group’s $7.00 Target Suggests Over 500% Upside Potential From Current Levels, Bringing A Fresh Perspective To Chemomab Therapeutics (Nasdaq: CMMB). A Market Cap Under $21M Keeps Chemomab Therapeutics (Nasdaq: CMMB) Under The Radar For Now—Where Some Of The Biggest Percentage Moves Tend To Begin. RSI Recently Dropped Below 30, A Technical Signal That Has Historically Preceded Trend Shifts In Similar Setups. The FDA Has Aligned On A Streamlined Phase 3 Design Using Real-World Clinical Outcomes—No Biopsies, No Long Delays. Keep Reading To See Why Chemomab Therapeutics (Nasdaq: CMMB) is Topping Our Watchlist This Morning… March 27, 2025 Dear Reader, Fresh 48-week trial data confirms continued biomarker improvements, safety, and reduced clinical deterioration in PSC patients treated with Nebokitug—adding momentum to Chemomab Therapeutics (Nasdaq: CMMB)’s path toward a pivotal Phase 3 trial. Patients saw reductions in ELF scores, improvements in liver stiffness, and better outcomes across inflammatory and fibrotic markers, with the 20 mg/kg dose showing especially strong effects. On the heels of this news, Chemomab Therapeutics (Nasdaq: CMMB) reached $1.38 in the early session, marking an approximate 18% move from yesterday’s $1.16 close—surpassing several key moving averages and triggering multiple bullish signals on TradingView’s dashboard. Biotech and pharma are some of the most exciting industries, where a single breakthrough can turn an under-the-radar company into a major market player overnight. This one has a float of less than 17M shares, which could set the stage for significant swings if attention starts to shift. Its market cap sits under $21M—a range where little-known companies have historically made their biggest moves when the right catalyst hits. And that catalyst may have just arrived: regulatory alignment that places it on track for a pivotal late-stage study targeting a serious condition with no approved therapies. We’re talking about Chemomab Therapeutics (Nasdaq: CMMB)—and the situation here is hard to ignore. With early-stage results already showing encouraging signals—and the FDA aligned on an efficient Phase 3 design—this clinical-stage company could be entering a critical stretch that few have spotted.  Michael Okunewitch, a Senior Research Analyst at Maxim Group, recently set a $7.00 target on Chemomab Therapeutics (Nasdaq: CMMB)—which suggests over 503% upside potential from Wednesday’s $1.16 close. That’s not just a projection—it’s a clear signal that something may be taking shape beneath the surface. With a float under 17M shares and a market cap below $21M, this is still very much under the radar—exactly where some of the biggest moves tend to begin. And with its RSI levels dipping below 30, Chemomab Therapeutics (Nasdaq: CMMB) appears to be heading towards “oversold territory” and potentially paving the way for a quick trend reversal.  Keep reading to see why Chemomab Therapeutics (Nasdaq: CMMB) is topping our watchlist this morning. The company’s lead program is targeting a rare and devastating liver condition where no approved therapies exist—one with significant unmet need and growing urgency. The Focus: A Rare Liver Disease With No Approved Options—Until Now? Primary Sclerosing Cholangitis (PSC) is a rare but devastating condition—marked by progressive inflammation and fibrosis of the bile ducts.  Over time, it blocks bile flow, damages the liver, and can lead to cancer, liver failure, or the need for a transplant.   Roughly 80,000 people across the U.S., Europe, and Japan are affected. And despite the severity, no approved therapies currently exist. That’s what makes Chemomab Therapeutics (Nasdaq: CMMB) stand out right now. Its lead candidate, Nebokitug, is designed to do something different—targeting a protein called CCL24, which plays a key role in the inflammation-fibrosis cycle at the core of PSC.  By blocking this pathway, Nebokitug has shown the potential to reduce immune cell recruitment, suppress fibroblast activation, and disrupt the self-reinforcing damage that drives disease progression. This isn't a theory. Chemomab has already run five clinical trials demonstrating both safety and biological activity—not just in PSC, but across multiple inflammatory and fibrotic conditions.  In its Phase 2 study, Nebokitug delivered improvements in key biomarkers tied to inflammation, fibrosis, and bile duct function.  Patients with more advanced PSC showed even greater benefit—an encouraging signal heading into the next stage. The drug also delivered dose-dependent target engagement, a favorable tolerability profile, and statistically significant improvements in liver stiffness, pruritus, and ELF scores.  That trifecta—fibrosis, inflammation, and bile duct health—represents the full scope of PSC pathology.  And so far, Nebokitug may be the only late-stage candidate to demonstrate consistent effects across all three. It’s not often a Phase 3-ready program comes with this kind of validation—and even fewer are flying this far under the radar. FDA Alignment Positions Chemomab Therapeutics (Nasdaq: CMMB) to Potentially Disrupt a $50B-Plus Market… After its End-of-Phase 2 meeting with the FDA, Chemomab Therapeutics (Nasdaq: CMMB) received alignment on a clear and efficient pivotal trial design.  The planned Phase 3 study will use clinically meaningful, event-based endpoints—tracking real-world outcomes such as the need for transplant, hospitalization due to liver complications, and other markers of disease progression. Importantly, this trial design avoids the need for liver biopsies or long, complex confirmatory studies—potentially accelerating execution and reducing complexity compared to many rare disease trials. The company is now preparing to initiate this late-stage study, with final protocol lock expected soon.  Meanwhile, an Open Label Extension is underway and could generate additional data that further supports Nebokitug’s potential role in this space. This progress comes at a time when the broader liver fibrosis treatment market is expanding rapidly—driven by rising incidence and unmet clinical needs.  Analysts forecast that the global liver fibrosis treatment market could grow from $20.35B in 2025 to approximately $52.26B by 2034, with the U.S. segment alone projected to more than double, from $5.41B to $14.18B over the same period. In a market this large—and this underserved—a differentiated approach like Nebokitug’s could represent a meaningful development. Not Just PSC: A Pipeline That Could Expand… While PSC is the lead indication, Chemomab Therapeutics (Nasdaq: CMMB) is also exploring Nebokitug for Systemic Sclerosis (SSc)—another rare fibro-inflammatory disease.  This program is already Phase 2-ready, with an open U.S. IND, Orphan Designation, and robust preclinical evidence supporting its mechanism. Research has shown elevated CCL24 levels in SSc patients and strong associations between those levels and clinical severity.  Animal models and human samples alike suggest CCL24 blockade could reduce skin and lung fibrosis—key symptoms of this challenging condition. If PSC paves the way, SSc could open a second major path forward. Recent Developments New Data on Nebokitug Revealed at CORA 2025… Fresh findings presented at the CORA 2025 Conference have spotlighted Nebokitug's potential impact in systemic sclerosis—an aggressive autoimmune condition with limited options. Researchers shared updated preclinical data confirming that elevated CCL24 levels, Nebokitug’s target, are highly correlated with disease progression and organ damage.  The company also highlighted that blocking CCL24 led to reduced fibrosis markers and inflammation in lung and skin tissue models—two areas central to systemic sclerosis.  This adds to the scientific validation supporting future clinical development of Nebokitug in this indication. Chemomab Shares 2024 Highlights and Lays Out Strategic Priorities… Chemomab’s end-of-year corporate update offers a clear picture of momentum and focus heading into 2025. In this comprehensive summary, the company reiterated its progress advancing Nebokitug in primary sclerosing cholangitis (PSC), including strong safety signals and promising biomarker improvements from the Phase 2 SPRING trial.  They also pointed to preparations underway for the Phase 3 study, anticipated key milestones in systemic sclerosis, and an early 2026 cash runway. The update reinforces a disciplined approach to development while emphasizing continued scientific and operational execution. FDA Feedback Clears the Way for Next-Stage Nebokitug Trial… Chemomab successfully completed its End-of-Phase 2 meeting with the FDA, resulting in alignment on a clear, event-based design for the Phase 3 trial in PSC. The meeting confirmed that clinical events such as disease-related hospitalizations, liver function decline, or transplant need will be used as endpoints—potentially removing the need for invasive procedures like liver biopsies.  The design aims to track real-world impact while enabling broader patient inclusion. This milestone significantly streamlines the company’s path forward and positions Nebokitug as a potential leader in a space with no approved therapies to date. Bottom Line… Chemomab Therapeutics (Nasdaq: CMMB) is navigating forward with: A Phase 3-ready program targeting a serious rare disease with no approved options A differentiated mechanism of action backed by clinical and preclinical data A low-float structure that could amplify attention as momentum builds A high target from a respected analyst, bringing this name into focus With multiple near-term catalysts, a streamlined regulatory path, and a candidate demonstrating effects across critical biomarkers—Chemomab Therapeutics (Nasdaq: CMMB) could soon move out from under-the-radar. This is one little-known company to keep an eye on. 5 Reasons Why Chemomab Therapeutics (Nasdaq: CMMB) is Topping Our Watchlist This Morning…  1. Small Float: With fewer than 17M shares listed, Chemomab Therapeutics (Nasdaq: CMMB) has the kind of potential that could amplify moves when attention builds. 2. Analyst Coverage: Maxim Group’s $7.00 target suggests over 500% upside potential from current levels, bringing a fresh perspective to Chemomab Therapeutics (Nasdaq: CMMB). 3. Under the Radar—For Now: A market cap under $21M keeps Chemomab Therapeutics (Nasdaq: CMMB) in rare territory—where some of the biggest percentage moves tend to begin. 4. Oversold Signals Triggered: RSI recently dropped below 30, a technical signal that has historically preceded trend shifts in similar setups. 5. Regulatory Greenlight Secured: The FDA has aligned on a streamlined Phase 3 design using real-world clinical outcomes—no biopsies, no long delays. Take A Look At Chemomab Therapeutics (Nasdaq: CMMB) While  It’s Still Early… Sometimes the companies hiding in plain sight are the ones worth circling twice. Chemomab Therapeutics (Nasdaq: CMMB) has a float under 17M, a market cap still under $21M, and a Phase 3 path now cleared by the FDA—no biopsies, no long-winded delays. Layer on strong Phase 2 data, an RSI in oversold territory, and a second indication waiting in the wings—and it’s not hard to see why this one could start moving faster than most are ready for. Maxim Group’s $7.00 target? That’s not hype—it’s a number that suggests over 500% upside potential for (CMMB). We already have (CMMB) at the top of our screens. Chemomab Therapeutics (Nasdaq: CMMB) reached $1.38 in the early session, marking an approximate 18% move from yesterday’s $1.16 close—surpassing several key moving averages and triggering multiple bullish signals. Is (CMMB) on your screen yet? Watch for my next update—it could be on its way to you at any moment. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 03/26/2025 and ending on 03/27/2025 to publicly disseminate information about (CMMB:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (CMMB:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/cmmb/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice